Liver concerns scupper Takeda's fasiglifam at Phase III
This article was originally published in Scrip
Despite the release of promising initial Phase III efficacy data earlier in the year, 2013 has not ended well for Takeda's first-in-class GPR40 agonist fasiglifam (TAK-875), with the company deciding to drop the oral diabetes drug for safety reasons.
You may also be interested in...
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.